Effective today, Jonathan Royce has officially taken on the role of CEO at Cavidi.
The company’s long-standing CEO, John Reisky de Dubnic, will continue to serve as Chairman of the Board following the leadership transition.
Under John’s guidance, Cavidi has undergone a remarkable transformation, most notably with the invention and patenting of its Binding Oligo Ladder Detection (BOLD) technology. In recent years, the company has entered a dynamic phase of product commercialization. Jonathan’s extensive experience and proven leadership in life sciences are expected to drive the next chapter of Cavidi’s growth—scaling operations and creating long-term value.
This transition comes at a pivotal moment, as Cavidi accelerates sales growth and prepares for new product launches. Bringing in a CEO with deep life science expertise and a strong presence in Uppsala positions the company for successful industrial scale-up.
“As Chairman, I will continue to lead the board and support Jonathan and the management team in every way I can,” said John Reisky de Dubnic. “The go-to-market strategy for BOLD and Exazym is clear. Jonathan brings outstanding experience in navigating the challenges ahead, and I am confident in the team’s ability to execute our business plan under his leadership.”
Jonathan is a seasoned C-suite executive with over 25 years in the life sciences sector, specializing in industrial biotechnology—from development and production to technical sales and marketing. He has held leadership roles and delivered results at companies including Millipore, GE Healthcare, Vironova, and Bio-Works Technologies. He holds a Master’s degree in Chemical Engineering from Northeastern University.